Interleukin-23: A New Atherosclerosis Target

Area of Science:

• Immunology
• Cardiovascular Disease
• Inflammation Biology

Background:

• Atherosclerosis is an inflammatory disease driven by an imbalance in anti-inflammatory and pro-inflammatory processes.
• Interleukin-23 (IL-23) is a cytokine implicated in chronic inflammatory and autoimmune diseases.
• IL-23 signaling involves the IL-23 receptor (IL-23R) and downstream pathways like JAK2/STAT.

Purpose of the Study:

• To investigate the role of Interleukin-23 (IL-23) as a potential therapeutic target for atherosclerosis.
• To elucidate the mechanisms by which IL-23 contributes to the inflammatory processes in atherosclerosis.

Main Methods:

• Review of existing evidence on IL-23's role in T cell differentiation and immune cell function.
• Analysis of IL-23 receptor (IL-23R) expression on immune cells like T cells, dendritic cells, and macrophages.
• Examination of IL-23 signaling pathways, including JAK2/STAT.

Main Results:

• IL-23 promotes T helper type 17 cell differentiation and exacerbates effector T lymphocyte/regulatory T cell imbalance.
• IL-23R expression on immune cells enhances their pro-inflammatory functions and recruitment to lesion sites.
• IL-23 signaling contributes to the pathogenesis of chronic inflammatory and autoimmune diseases.

Conclusions:

• IL-23 plays a significant role in inducing and exacerbating inflammation in atherosclerosis.
• Targeting the IL-23/IL-23R pathway presents a promising therapeutic strategy for atherosclerosis.
• Further research is required to fully understand IL-23's precise role and signaling in atherosclerosis.